Recurrent S. Aureus Infections in Osteoarticular Infections (RELAPSTAPH)

January 19, 2022 updated by: Hospices Civils de Lyon

Staphylococcus aureus osteoarticular infections, in particular those associated with the presence of implant, relapse in 20% of cases. Currently, the reasons for these relapses are poorly understood, whether on the microbiological or clinical side.

The aim of this study is to improve knowledge on persistence of mechanisms of S. aureus

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lyon, France, 69004
        • Recruiting
        • Hospices Civils de Lyon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients having had an osteoarticular infection with or without material due to S. aureus and treated at CRIOAc Lyon, presenting a recurrence of S. aureus infection

Description

Inclusion Criteria:

  • patients having had an osteoarticular infection with or without material due to S. aureus presenting a recurrence of S. aureus infection

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
relapse due to S. aureus
patients having had an initial infection due to S. aureus and who present a relapse with persistence of S. aureus
Other: relapse due to S. aureus
to find out if it is the same S. aureus in both infections

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of patients having had an osteoarticular infection due to S. aureus
Time Frame: between 2015 and 2020
proportion of patients having had an osteoarticular infection due to S. aureus
between 2015 and 2020
Description of patients having had an osteoarticular infection due to S. aureus
Time Frame: between 2015 and 2020
type of patients: age, BMI, comorbidities...
between 2015 and 2020
Description of Bone and Joint Iinfection/Prosthesis Joint Infection
Time Frame: between 2015 and 2020
implant or prosthesis or not, acute/ chronic, bacteriology
between 2015 and 2020

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of patients having had a relapse due to persistence of S. aureus
Time Frame: between 2015 and 2020
proportion of patients having had an osteoarticular infection due persistence of S. aureus
between 2015 and 2020
rate of S. aureus strain identical between the initial episode and the relapse
Time Frame: between 2015 and 2020
proportion of relapse due to the same strain of S. aureus than in the initial episode
between 2015 and 2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2021

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

January 1, 2023

Study Registration Dates

First Submitted

January 13, 2021

First Submitted That Met QC Criteria

January 13, 2021

First Posted (Actual)

January 15, 2021

Study Record Updates

Last Update Posted (Actual)

January 20, 2022

Last Update Submitted That Met QC Criteria

January 19, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 281

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Staphylococcus Aureus Infection

Clinical Trials on relapse due to S. aureus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe